Late last month, Gossamer Bio filed to raise up to $230 million in a fixed-price IPO so it could go public despite the partial shutdown of the U.S. government. Now that the government has reopened, the San Diego biotech has returned to its original plan, pricing its traditional IPO at $276 million. The San Diego biotech priced 17,250,000 shares at $16 apiece, blowing well past its $230 million fixed-price target. As the shutdown continued, Reuters reported that some 80 compan